If FCR will be the therapy of selection, warning have to be taken in patients with NOTCH1 mutations, in whom rituximab seems to get minor added value.fifty nine Other genomic subgroups, such as individuals with BIRC3 mutations show up to derive very little gain from CIT,111,112 but these final results https://abdulc603rzc4.prublogger.com/profile